Pfizer stands as a significant force in the oncology sector, with a diverse portfolio that spans breast, genitourinary, thoracic, gastrointestinal, and hematologic cancers. The company’s established array of marketed cancer treatments is bolstered by an extensive pipeline that includes small-molecule drugs, antibody-drug conjugates, and immuno-oncology biologics.
Financial Overview of Oncology Sales
Oncology accounts for approximately 27% of Pfizer’s total revenues. In the second quarter of 2026, oncology revenues reached $4.17 billion, reflecting a 3% increase, largely due to operational growth of 2%. Key contributors to this growth include Padcev, Lorbrena, and Braftovi/Mektovi.
Lorbrena exhibited a remarkable 37% increase in operational revenue, totaling $354 million. However, Adcetris faced a decline of 23%, earning $196 million, while Inlyta’s sales dipped 12% to $218 million. Conversely, Braftovi/Mektovi reported a 23% increase to $223 million. The recently launched drug, Elrexfio, also showed promise with sales of $89 million, marking a 5% year-over-year increase.
Padcev: The Cornerstone of Growth
Padcev has emerged as a pivotal driver of growth for Pfizer’s oncology segment, benefiting from robust demand, particularly in the first-line treatment of metastatic urothelial cancer and the recent indication for muscle-invasive bladder cancer. The FDA’s approval of Padcev in combination with Merck’s Keytruda for this broader indication significantly enhances its market potential, potentially impacting over 42,000 patients in the U.S. The approval was supported by phase III trial data demonstrating a 35% reduction in mortality risk.
Expansion into Biosimilars
Pfizer has also made strides into the oncology biosimilars market, marketing six biosimilars that collectively generated $768 million in sales during the first half of 2026, reflecting a 23% year-over-year growth. This expansion underscores Pfizer’s strategic commitment to diversifying its oncology offerings.
Advancements in Clinical Pipeline
The company continues to progress its oncology clinical pipeline, targeting various cancer types, including breast, thoracic, gastrointestinal, and blood cancers. Notable candidates have reached late-stage development, such as atirmociclib and sigvotatug vedotin. Additionally, Pfizer is awaiting regulatory approval for sasanlimab in the EU.
The Promise of PF-08634404
Among the promising candidates in Pfizer’s oncology pipeline is PF-08634404, a dual PD-1/VEGF inhibitor licensed from Chinese biotech firm 3SBio in 2025. Pfizer has initiated nine studies for PF-08634404, including two pivotal phase III trials for first-line metastatic colorectal cancer and non-small cell lung cancer (NSCLC). Further phase II studies for small-cell lung cancer and gastroesophageal cancers are also underway. Pfizer envisions PF-08634404 as a cornerstone therapy across multiple tumor types, with aspirations for eight or more blockbuster oncology medicines in the portfolio by 2030.
Label Expansion Initiatives
Pfizer is actively working to broaden the indications for its existing oncology drugs, including Padcev, Tuksya, and Elrexfio, among others. This strategy aims to leverage the strengths of its current offerings while exploring new therapeutic avenues.
Competitive Landscape in Oncology
As one of the largest manufacturers of cancer medications, Pfizer competes with other major players in the oncology market, including Johnson & Johnson, AstraZeneca, Merck, and Bristol-Myers Squibb.
For instance, oncology represents nearly 29% of Johnson & Johnson’s total revenues, with a 16.9% increase in oncology revenues to $14.4 billion in the first half of 2026. Similarly, AstraZeneca’s oncology segment accounts for about 46% of its overall revenue, driven by strong performances from drugs like Tagrisso and Lynparza.
Stock Performance and Valuation
In terms of stock performance, Pfizer’s shares have increased by 12.3% this year, slightly lagging behind the industry’s 13.9% rise. From a valuation perspective, Pfizer trades at a forward price/earnings ratio of 9.48, which is below the industry average of 18.71 but above its five-year mean of 9.25.
The Zacks Consensus Estimate for Pfizer’s earnings per share has seen a slight uptick, moving from $2.96 to $2.98 for 2026, while estimates for 2027 increased from $2.85 to $2.94 over the past month. Currently, Pfizer holds a Zacks Rank of #3 (Hold).
Conclusion
Pfizer’s strategic maneuvers in oncology reflect its commitment to addressing a dynamic market with a comprehensive portfolio and an innovative pipeline. With key growth drivers like Padcev and promising candidates such as PF-08634404, the company is well-positioned to maintain its leadership in cancer treatment. As Pfizer continues to expand its offerings, the future of its oncology franchise appears bright and full of potential.
- Key Takeaways:
- Pfizer’s oncology sales account for 27% of total revenue.
- Padcev is a significant growth driver, with expanded indications boosting its market potential.
- The company is actively developing its clinical pipeline with promising candidates like PF-08634404.
- Pfizer is also venturing into the biosimilars market, contributing to significant revenue growth.
- Stock performance remains strong, with favorable earnings estimates for the coming years.
Read more → www.theglobeandmail.com